Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ adverse effects
Carcinoma, Hepatocellular
/ blood
Female
Humans
Liver Neoplasms
/ blood
Male
Middle Aged
Predictive Value of Tests
Protein Kinase Inhibitors
/ adverse effects
Retrospective Studies
Sodium
/ blood
Sorafenib
/ adverse effects
Time Factors
Treatment Outcome
alpha-Fetoproteins
/ metabolism
Hepatocellular carcinoma
Serum sodium
Sorafenib
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
18
02
2020
accepted:
30
05
2020
pubmed:
20
6
2020
medline:
31
8
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
Although the serum sodium level has been reported to be a prognostic and predictive marker for the therapeutic effects of lung cancer and renal cell carcinoma treated with molecular targeted therapy, the serum sodium level has not been investigated in hepatocellular carcinoma (HCC) patients treated with sorafenib. The aim of our analysis was to assess the prognostic role of serum sodium levels in these patients. We retrospectively analyzed 341 HCC patients treated with sorafenib between 2009 and 2012 in our hospital and other related institutions. A total of 178 patients were enrolled in this study. The median age was 72 years (44-88), and 148 patients (83%) were male. The median overall survival (OS) was 12.9 months, and the median time to progression (TTP) was 3.1 months. Hyponatremia (hazard ratio (HR) 1.78, 95% confidence interval (CI) 1.26-2.52), a lower sodium level (HR 1.57, 95% CI 1.07-2.80), and a high level of α-fetoprotein (AFP) (≥ 200 ng/mL) (HR 1.78, 95% CI 1.26-2.52) were independent prognostic factors for TTP. We also categorized the patients into three groups according to serum sodium and AFP levels: Group A (n = 39) (serum sodium > 140 mEq/L, AFP < 200 ng/mL), Group C (n = 58) (serum sodium ≤ 140 mEq/L, AFP ≥ 200 ng/mL), and Group B (n = 81) (other patients). Significantly longer TTP and OS were observed in the following order: Groups A, C, and B. Serum sodium levels are associated with the effectiveness of sorafenib. The serum sodium level can predict the therapeutic effect of sorafenib in advanced HCC patients.
Sections du résumé
BACKGROUND AND AIM
Although the serum sodium level has been reported to be a prognostic and predictive marker for the therapeutic effects of lung cancer and renal cell carcinoma treated with molecular targeted therapy, the serum sodium level has not been investigated in hepatocellular carcinoma (HCC) patients treated with sorafenib. The aim of our analysis was to assess the prognostic role of serum sodium levels in these patients.
METHODS
We retrospectively analyzed 341 HCC patients treated with sorafenib between 2009 and 2012 in our hospital and other related institutions.
RESULTS
A total of 178 patients were enrolled in this study. The median age was 72 years (44-88), and 148 patients (83%) were male. The median overall survival (OS) was 12.9 months, and the median time to progression (TTP) was 3.1 months. Hyponatremia (hazard ratio (HR) 1.78, 95% confidence interval (CI) 1.26-2.52), a lower sodium level (HR 1.57, 95% CI 1.07-2.80), and a high level of α-fetoprotein (AFP) (≥ 200 ng/mL) (HR 1.78, 95% CI 1.26-2.52) were independent prognostic factors for TTP. We also categorized the patients into three groups according to serum sodium and AFP levels: Group A (n = 39) (serum sodium > 140 mEq/L, AFP < 200 ng/mL), Group C (n = 58) (serum sodium ≤ 140 mEq/L, AFP ≥ 200 ng/mL), and Group B (n = 81) (other patients). Significantly longer TTP and OS were observed in the following order: Groups A, C, and B.
CONCLUSION
Serum sodium levels are associated with the effectiveness of sorafenib. The serum sodium level can predict the therapeutic effect of sorafenib in advanced HCC patients.
Identifiants
pubmed: 32556820
doi: 10.1007/s10620-020-06380-6
pii: 10.1007/s10620-020-06380-6
doi:
Substances chimiques
AFP protein, human
0
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
alpha-Fetoproteins
0
Sodium
9NEZ333N27
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1720-1729Références
Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604.
doi: 10.1038/s41575-019-0186-y
Global Burden of Disease Cancer Collaboration, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017; 3:524–548.
Wallace MC, Preen D, Jeffrey GP, et al. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765–779.
doi: 10.1586/17474124.2015.1028363
Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: our experience and literature review. Hepatol Res 2014.
Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253(3): 453–469. Overall, the 5-year survival rate for patients with HCC is less than 20% (Global Cancer Facts & Figures, 3rd Edition. Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-044738 . pdf.
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med.. 2008;359:378–390.
doi: 10.1056/NEJMoa0708857
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol.. 2009;10:25–34.
doi: 10.1016/S1470-2045(08)70285-7
Haydar AA, Mukherji D, Faraj W, et al. Challenges in combining antiangiogenic therapy with transarterial chemoembolization for hepatocellular carcinoma. Gastrointest Cancer Res.. 2014;7:98–102.
pubmed: 25276263
pmcid: 4171975
Erhardt A, Kolligs F, Dollinger M, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer Chemother Pharmacol.. 2014;74:947–954.
doi: 10.1007/s00280-014-2568-8
Shen A, Tang C, Wang Y, et al. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma. J Clin Gastroenterol.. 2013;47:871–880.
doi: 10.1097/MCG.0b013e3182a87cfd
Nishikawa H, Takeda H, Tsuchiya K, et al. Sorafenib therapy for BCLC stage B/C hepatocellular carcinoma; clinical outcome and safety in aged patients: a multicenter study in Japan. J Cancer. 2014;5:499–509.
doi: 10.7150/jca.9257
Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009;14:95–100.
doi: 10.1634/theoncologist.2008-0185
Lee IC, Chen YT, Chao Y, et al. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore). 2015;94:e688.
doi: 10.1097/MD.0000000000000688
Brunetti O, Gnoni A, Licchetta A, et al. Predictive and prognostic factors in HCC patients treated with Sorafenib. Medicina (Kaunas). 2019. 55(10).
Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol.. 2012;57:821–829.
doi: 10.1016/j.jhep.2012.06.014
Llovet JM, Peña CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res.. 2012;18:2290–2300.
doi: 10.1158/1078-0432.CCR-11-2175
Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603–611.
doi: 10.1148/radiol.13130150
Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87:22–31.
doi: 10.1159/000368142
Printz C. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer.. 2009;115(20):4646.
doi: 10.1002/cncr.24673
Takeda H, Nishikawa H, Osaki Y, et al. Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. Hepatol Res.. 2015;45:E130–E140.
doi: 10.1111/hepr.12480
Kaneko S, Ikeda K, Matsuzaki Y, et al. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol.. 2016;51:1011–1021.
doi: 10.1007/s00535-016-1173-5
Imanaka K, Ohkawa K, Tatsumi T, et al. Impact of branched-chain amino acid supplementation on survival in patients with advanced hepatocellular carcinoma treated with sorafenib: a multicenter retrospective cohort study. Hepatol Res. 2016;46:1002–1010.
doi: 10.1111/hepr.12640
Casadei Gardini A, Faloppi L, De Matteis S, et al. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: validation study and biological rationale. Eur J Cancer. 2017;86:106–114.
doi: 10.1016/j.ejca.2017.09.003
Ogasawara S, Chiba T, Ooka Y, et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs.. 2015;33:729–739.
doi: 10.1007/s10637-015-0237-3
Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol.. 2012;56:1080–1088.
doi: 10.1016/j.jhep.2011.12.009
Branco F, Alencar RS, Volt F, et al. The impact of early dermatologic events in the survival of patients with hepatocellular carcinoma treated with sorafenib. Ann Hepatol.. 2017;16:263–268.
doi: 10.5604/16652681.1231587
Reig M, Torres F, Rodriguez-Lope C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol.. 2014;61:318–324.
doi: 10.1016/j.jhep.2014.03.030
Wang W, Bai W, Wang E, et al. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. Int J Cancer. 2017;140:390–399.
doi: 10.1002/ijc.30451
Schutz FA, Xie W, Donskov F, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol. 2014;65(4):723–730.
doi: 10.1016/j.eururo.2013.10.013
Takeda H, Nishikawa H, Osaki Y, et al. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int. 2015;35:1581–1589.
doi: 10.1111/liv.12591
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.. 2010;30:52–60.
doi: 10.1055/s-0030-1247132
Salvaggio G, Furlan A, Agnello F, et al. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiol Med.. 2014;119:215–221.
doi: 10.1007/s11547-013-0332-5
European Association for The Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol.. 2012;56:908–943.
doi: 10.1016/j.jhep.2011.12.001
Cheng AL, Amarapurkar D, Chao Y, et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel. Liver Int.. 2014;34:174–183.
doi: 10.1111/liv.12314
Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers.. 2016;14:16018.
doi: 10.1038/nrdp.2016.18
Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
doi: 10.1016/j.jhep.2018.03.019
Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67:999–1008.
doi: 10.1016/j.jhep.2017.06.026
Wang P, Tan G, Zhu M, et al. Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and metaanalysis. Expert Rev Gastroenterol Hepatol. 2018;12:1–8.
doi: 10.1080/17474124.2017.1373018
Sánchez AIP, et al. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett. 2018;15:8863–8870.
pubmed: 29805623
pmcid: 5950578
Nishikawa H, et al. Hyponatremia in hepatocellular carcinoma complicating with cirrhosis. J Cancer.. 2015;6:482–489.
doi: 10.7150/jca.11665
Marroncini G, Fibbi B, Errico A, et al. Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro. Endocrine. 2020;67:473–484.
doi: 10.1007/s12020-019-02135-0